Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229366 | 0.86 | MAP2K1 (0.75) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL3223974 | 0.85 | MAP2K1 (0.71) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL3228759 | 0.80 | IGF1R (0.81) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL5255055 | 0.79 | MAP2K1 (0.78) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL4443456 | 0.79 | IGF1R (1.00) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL7688305 | 0.79 | MAP2K1 (0.65) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL3219505 | 0.78 | MAP2K1 (0.75) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2961308 | 0.77 | IGF1R (0.89) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL4869423 | 0.77 | IGF1R (0.87) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 | |
| SCHEMBL2971320 | 0.77 | IGF1R (0.88) | IGF1RMAP2K1MAPK3MAPK1MAP3K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | IGF1R 1028/4885MAP2K1 568/4885MAPK3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.